Cyclin-dependent kinase inhibitor p27(Kip1) expression in transitional cell carcinoma of renal pelvis and ureter

Cancer Letters

Volumn 150, Issue 2, 2000, Pages 183-189

  Masuda, Mistunobu ^a   Takano, Yasuo ^b   Iki, Masayuki ^c   Makiyama, Kazuhide ^a   Ikeda, Ichiro ^a   Noguchi, Sumio ^a   Hasegawa, Yukio ^d   Hosaka, Masahiko ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b Kitasato University   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Department of Pathology   (Japan)

Author keywords

Carcinoma; Kidney neoplasm; p27(Kip1); Transitional cell; Ureteral neoplasm

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P27;

ADULT; AGED; ARTICLE; CANCER GRADING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY PELVIS CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; URETER CARCINOMA; URINARY TRACT CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; HUMANS; KIDNEY NEOPLASMS; KIDNEY PELVIS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; TUMOR SUPPRESSOR PROTEINS; URETERAL NEOPLASMS;

EID: 0034001045     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00389-4     Document Type: Article

References (36)

1. Sherr C.J., Roberts J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1995;1149-1163.
2. Hirama T., Koeffler H.P. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood. 86:1995;841-854.
3. Sherr C.J. Cancer cell cycles. Science. 274:1996;1672-1677.
4. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 78:1994;59-66.
5. Toyoshima H., Hunter T. p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell. 78:1994;67-74.
6. Kip2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 9:1995;639-649.
7. Cip1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev. 15:1995;650-662.
8. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev. 8:1994;9-22.
9. Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature. 372:1994;570-573.
10. Kip1) of cyclin-dependent kinase 4 activation. Cell. 79:1994;487-496.
11. Fang F., Orend G., Watanabe N., Hunter T., Ruoslahti E. Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science. 271:1996;499-502.
12. Kip1 for restriction point control of the fibroblast cell cycle. Science. 272:1996;877-880.
13. Kip1 in malignant melanoma. Inverse correlation with disease-free survival. Am. J. Pathol. 153:1998;305-312.
14. Loda M., Cukor B., Tam S.W., Lavin P., Fiorentino M., Draetta G.F., Jessup J.M., Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med. 3:1997;231-234.
15. Tan P., Cady B., Wanner M., Worland P., Cukor B., Magi-Galluzzi C., Lavin P., Draetta G., Pagano M., Loda M. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res. 57:1997;1259-1263.
16. Mori M., Mimori K., Shiraishi T., Tanaka S., Ueo H., Sugimachi K., Akiyoshi T. p27 expression and gastric carcinoma. Nature Med. 3:1997;593.
17. Yang R.M., Naitoh J., Murphy M., Wang H.-J., Phillipson J., deKernion J.B., Loda M., Reiter R.E. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J. Urol. 159:1998;941-945.
18. Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J. Natl. Cancer Inst. 90:1998;916-920.
19. Kip1 expression and progression of human esophageal squamous cell carcinoma. Int. J. Cancer. 79:1998;439-443.
20. Esposito V., Baldi A., Luca A.D., Groger A.M., Loda M., Giordano G.G., Caputi M., Baldi F., Pagano M., Giordano A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 57:1997;3381-3385.
21. Kip1 is a new prognostic marker associated with survival in epithelial ovarian tumors. Am. J. Pathol. 154:1999;119-125.
22. Kip1 expression and interaction with other cell cycle-associated proteins in mammary carcinoma. J. Pathol. 187:1999;200-206.
23. TNM Atlas: Renal Pelvis and Ureter. Hermanek P., Hutter R.V.P., Sobin L.H., Wagner G., Wittekind Ch. 4th Edition :1997;303-308 Springer, New York.
24. Sakamoto Y., Ishiguro G., Kitagawa G. Akaike Information Criterion Statistics. 1986;56-85 Reidel, Dordrecht, Nederland.
25. Kip1 protein in human prostate cancer correlates with tumor grade. Clin. Cancer Res. 3:1997;2269-2274.
26. Kip1 in prostatic adenocarcinoma. Mod. Pathol. 11:1998;324-328.
27. Kip1 and degree of malignancy in human breast and colorectal cancers. Proc. Natl. Acad. Sci. USA. 94:1997;6380-6385.
28. Kip1 is associated with advanced stage and invasiveness of gastric carcinoma. Jpn. J. Cancer Res. 88:1997;625-629.
29. Kip1 in human breast cancers. Clin. Cancer Res. 3:1997;1879-1887.
30. Kip1 is an indicator of malignant behavior in oral squamous cell carcinoma. Cancer. 83:1998;2447-2555.
31. Akaza H., Koiso K., Niijima T. Clinical evaluation of urothelial tumors of the renal pelvis and ureter based on a new classification system. Cancer. 59:1987;1369-1375.
32. Huben R.P., Mounzer A.M., Murphy G.P. Tumor grade and stage as a prognostic variables in upper tract urothelial tumors. Cancer. 62:1988;2016-2020.
33. Masuda M., Iki M., Takano Y., Asakura T., Noguchi S., Ikeda I., Kubota Y., Hosaka M. J. Urol. 1996;1551877-1551881.
34. Fang F., Orend G., Watanabe N., Hunter T., Ruoslahti E. Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science. 271:1996;499-502.
35. Zhu X., Ohtsubo M., Böhmer R.M., Roberts J.M., Assoian R.K. Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J. Cell Biol. 133:1996;391-403.
36. Thomas G.V., Szigeti K., Murphy M., Draetta G., Pagano M., Loda M. Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am. J. Pathol. 153:1998;681-687.